368 related articles for article (PubMed ID: 8226563)
1. Management of immunocompromised patients with evidence of an invasive mycosis.
Walsh TJ
Hematol Oncol Clin North Am; 1993 Oct; 7(5):1003-26. PubMed ID: 8226563
[TBL] [Abstract][Full Text] [Related]
2. The rationale of combination antifungal therapy in severely immunocompromised patients: empiricism versus evidence-based medicine.
Chamilos G; Kontoyiannis DP
Curr Opin Infect Dis; 2006 Aug; 19(4):380-5. PubMed ID: 16804387
[TBL] [Abstract][Full Text] [Related]
3. The immune response to fungal infections.
Shoham S; Levitz SM
Br J Haematol; 2005 Jun; 129(5):569-82. PubMed ID: 15916679
[TBL] [Abstract][Full Text] [Related]
4. [Drug resistance in the treatment of invasive fungal infections].
Nordøy I; Gaustad P
Tidsskr Nor Laegeforen; 2008 Nov; 128(22):2607-11. PubMed ID: 19023376
[TBL] [Abstract][Full Text] [Related]
5. Recent advances in antifungal prevention and treatment.
Groll AH; Tragiannidis A
Semin Hematol; 2009 Jul; 46(3):212-29. PubMed ID: 19549575
[TBL] [Abstract][Full Text] [Related]
6. Fungal infections in the immunocompromised host.
Hawkins C; Armstrong D
Clin Haematol; 1984 Oct; 13(3):599-630. PubMed ID: 6388935
[TBL] [Abstract][Full Text] [Related]
7. Management of mycoses in surgical patients -- review of the literature.
Holzheimer RG; Dralle H
Eur J Med Res; 2002 May; 7(5):200-26. PubMed ID: 12069912
[TBL] [Abstract][Full Text] [Related]
8. The place for itraconazole in treatment.
Maertens J; Boogaerts M
J Antimicrob Chemother; 2005 Sep; 56 Suppl 1():i33-i38. PubMed ID: 16120632
[TBL] [Abstract][Full Text] [Related]
9. Treatment of fungal and other opportunistic infections in immunocompromised patients.
Wade JC
Leukemia; 1997 May; 11 Suppl 4():S38-9. PubMed ID: 9179282
[TBL] [Abstract][Full Text] [Related]
10. Current therapeutic approaches to fungal infections in immunocompromised hematological patients.
Pagano L; Caira M; Valentini CG; Posteraro B; Fianchi L
Blood Rev; 2010 Mar; 24(2):51-61. PubMed ID: 20056300
[TBL] [Abstract][Full Text] [Related]
11. Recent progress and current problems in management of invasive fungal infections in patients with neoplastic diseases.
Walsh TJ; Lee JW; Roilides E; Pizzo PA
Curr Opin Oncol; 1992 Aug; 4(4):647-55. PubMed ID: 1511021
[TBL] [Abstract][Full Text] [Related]
12. Evaluation and management of fungal infections in immunocompromised patients.
Venkatesan P; Perfect JR; Myers SA
Dermatol Ther; 2005; 18(1):44-57. PubMed ID: 15842612
[TBL] [Abstract][Full Text] [Related]
13. [Fungal infections in transplantation patients].
Colomba C; Antinori S
Recenti Prog Med; 2003 Nov; 94(11):516-28. PubMed ID: 14679922
[TBL] [Abstract][Full Text] [Related]
14. Improved outcomes associated with advances in therapy for invasive fungal infections in immunocompromised hosts.
Metcalf SC; Dockrell DH
J Infect; 2007 Oct; 55(4):287-99. PubMed ID: 17697716
[TBL] [Abstract][Full Text] [Related]
15. Recent advances and challenges in the treatment of invasive fungal infections.
Shao PL; Huang LM; Hsueh PR
Int J Antimicrob Agents; 2007 Dec; 30(6):487-95. PubMed ID: 17961990
[TBL] [Abstract][Full Text] [Related]
16. High cure rate of invasive fungal infections in immunocompromised children using ambisome.
Ringdén O; Tollemar J; Dahllöf G; Tydén G
Transplant Proc; 1994 Feb; 26(1):175-7. PubMed ID: 8108927
[No Abstract] [Full Text] [Related]
17. Update on antifungal treatment of invasive Candida and Aspergillus infections.
Maschmeyer G; Ruhnke M
Mycoses; 2004 Aug; 47(7):263-76. PubMed ID: 15310328
[TBL] [Abstract][Full Text] [Related]
18. Pediatric antifungal therapy. Part I: focus on febrile neutropenia, invasive aspergillosis, combination antifungal therapy and invasive candidiasis in immunocompromised pediatric patients.
Allen U; Bow E; Doyle J; Richardson S; Robinson J; Rotstein C; Davies D; Hui C; Le Saux N; Laverdiere M; Read S
Minerva Pediatr; 2010 Feb; 62(1):57-69. PubMed ID: 20212399
[TBL] [Abstract][Full Text] [Related]
19. Epidemiology of invasive fungal infection.
Castón-Osorio JJ; Rivero A; Torre-Cisneros J
Int J Antimicrob Agents; 2008 Nov; 32 Suppl 2():S103-9. PubMed ID: 19013332
[TBL] [Abstract][Full Text] [Related]
20. Prophylaxis, pre-emptive or empirical antifungal therapy: which is best in non-lung transplant recipients?
Salavert M
Int J Antimicrob Agents; 2008 Nov; 32 Suppl 2():S149-53. PubMed ID: 19013340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
